Vincerx Pharma to Participate in the 2021 Wells Fargo Virtual Healthcare Conference

On September 7, 2021 Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, reported that Vincerx’s management team will participate in a fireside chat at the 2021 Wells Fargo Virtual Healthcare Conference, to be held September 9-10, 2021 (Press release, Vincerx Pharma, SEP 7, 2021, View Source [SID1234587324]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Vincerx Fireside Chat Details

Date: Thursday, September 9, 2021

Time: 4:40 PM Eastern Time

Webcast: View Source
The presentation will be webcast live and archived for 90 days in the Investors section of the Company’s website.

CytomX Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

On September 7, 2021 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody technology platform, reported that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in a virtual fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference, being held from September 13-15, 2021 (Press release, CytomX Therapeutics, SEP 7, 2021, View Source [SID1234587323]). In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The pre-recorded fireside chat will be made available on the Events and Presentations page of CytomX’s website at www.cytomx.com for on-demand viewing starting Monday, September 13, 2021 at 7:00 a.m. ET. An archived replay will be available for 90 days following the event.

Inhibikase Therapeutics to Present at Upcoming H.C. Wainwright 23rd Annual Global Investment Conference

On September 7, 2021 Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders inside and outside of the brain, reported that Dr. Milton Werner, Ph.D., Chief Executive Officer of Inhibikase, will present at the H.C. Wainwright 23rd Annual Global Investment Conference, being held from September 13-15, 2021 (Press release, Inhibikase Therapeutics, SEP 7, 2021, View Source [SID1234587322]). Details for the presentation are below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 23rd Annual Global Investment Conference
Date: Monday, September 13, 2021
Time: 7:00am ET

A webcast of the presentation will be available for on-demand viewing under "News & Events" in the Investors section of the Company’s website, www.inhibikase.com. An archived replay of the webcast will be available for approximately 30 days following the event.

Protara Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

On September 7, 2021 Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, reported that management will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually on September 13-15, 2021 (Press release, Protara Therapeutics, SEP 7, 2021, View Source [SID1234587321]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The prerecorded presentation will become available on Monday, September 13, 2021 at 7:00am ET and can be accessed by visiting the Events and Presentations section of the Company’s website: View Source The webcast will be archived on the Company’s website for 90 days following the presentation.

Genocea to Present at Upcoming Scientific and Investor Conferences

On September 7, 2021 Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, reported that senior leadership plans to present at the following virtual conferences in September (Press release, Genocea Biosciences, SEP 7, 2021, View Source [SID1234587320]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Scientific conferences:

Event: Next Generation Cancer Vaccine Development Summit – Details
Topic: Neoantigen selection to identify immunogenic tumor specific targets personalized to each patient’s tumor and immune system
Format: Post Conference Workshop
Date: Thursday, September 9th
Time: 1:00 p.m. ET
Investor conferences:

Event: H.C. Wainwright 22nd Annual Global Investment Conference (virtual) – Details
Format: Presentation
Date: Monday, September 13th
Time: 7:00 a.m. ET

Event: Baird Global Healthcare Conference 2021 (virtual) – Details
Format: Presentation
Date: Wednesday, September 15th
Time: 11:25 a.m. ET